Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients-Reference-Cited by-同舟云学术

Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Published:2012-02-09 Issue:7 Volume:72 Page:1621-1631
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Pesonen Sari,Diaconu Iulia,Kangasniemi Lotta,Ranki Tuuli,Kanerva Anna,Pesonen Saila K.,Gerdemann Ulrike,Leen Ann M.,Kairemo Kalevi,Oksanen Minna,Haavisto Elina,Holm Sirkka-Liisa,Karioja-Kallio Aila,Kauppinen Satu,Partanen Kaarina P. L.,Laasonen Leena,Joensuu Tima,Alanko Tuomo,Cerullo Vincenzo,Hemminki Akseli

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial;Clinical Cancer Research;2024-03-27

2. Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth;Vaccines;2024-03-21

3. Cancer Type-Specific Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis;2024

4. Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model;Frontiers in Oncology;2023-11-20

5. Les virus oncolytiques : acteurs et vecteurs de protéines thérapeutiques contre les tumeurs;médecine/sciences;2023-11